Bioline RX Ltd Sponsored ADR Stock

$3.63

4.31% today

Nasdaq, Feb 05, 04:15 pm CET

ISIN

US09071M1062

Symbol

BLRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Bioline RX Ltd Sponsored ADR Stock price

$3.48

-91.72 96.34% 5Y

Nasdaq, Closing price Tue, Feb 04 2025

+0.09 2.65%

ISIN

US09071M1062

Symbol

BLRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$12.95m
Enterprise Value	$13.39m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	0.61
P/S ratio (TTM) P/S ratio	0.59
P/B ratio (TTM) P/B ratio	0.82
Revenue (TTM) Revenue	$21.99m
EBIT (operating result TTM) EBIT	$-27.85m
Free Cash Flow (TTM) Free Cash Flow	$-30.35m
Cash position	$29.17m
EPS (TTM) EPS	$-10.72
P/E forward	negative
P/S forward	0.52
EV/Sales forward	0.54
Short interest	1.33%

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Get Started for Free Today

Bioline RX Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Bioline RX Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	22 22	- 100%
- Direct Costs	7.52 7.52	764% 764% 34%
Gross Profit	14 14	1,763% 1,763% 66%
- Selling and Administrative Expenses	29 29	16% 16% 132%
- Research and Development Expense	10 10	19% 19% 47%
EBITDA	-25 -25	36% 36% -113%
- Depreciation and Amortization	2.92 2.92	236% 236% 13%
EBIT (Operating Income) EBIT	-28 -28	30% 30% -127%
Net Profit	-20 -20	62% 62% -91%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Bioline RX Ltd Sponsored ADR Stock News

Neutral

PRNewsWire

●

15 days ago

BioLineRx Issues Letter to Shareholders

- Company outlines strategic long-term vision and financial outlook - TEL AVIV, Israel , Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today issued the following letter to shareholders.

Neutral

PRNewsWire

●

19 days ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

TEL AVIV, Israel , Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary...

Neutral

PRNewsWire

●

about one month ago

BioLineRx Announces $10 Million Registered Direct Offering

TEL AVIV, Israel , Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000 of the Company's American Depositary Shares (ADSs) (or...

More Bioline RX Ltd Sponsored ADR News

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Head office	Israel
CEO	Philip Serlin
Employees	38
Founded	2003
Website	www.biolinerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now